Literature DB >> 31467120

ERS/EAACI statement on severe exacerbations in asthma in adults: facts, priorities and key research questions.

Arnaud Bourdin1, Leif Bjermer2, Christopher Brightling3, Guy G Brusselle4, Pascal Chanez5, Kian Fan Chung6, Adnan Custovic7, Zuzana Diamant8,9, Sarah Diver10, Ratko Djukanovic11, Dominique Hamerlijnck12, Ildikó Horváth13, Sebastian L Johnston14, Frank Kanniess15, Nikos Papadopoulos16,17, Alberto Papi18, Richard J Russell19, Dermot Ryan20,21, Konstantinos Samitas22, Thomy Tonia23, Eleftherios Zervas24, Mina Gaga25.   

Abstract

Despite the use of effective medications to control asthma, severe exacerbations in asthma are still a major health risk and require urgent action on the part of the patient and physician to prevent serious outcomes such as hospitalisation or death. Moreover, severe exacerbations are associated with substantial healthcare costs and psychological burden, including anxiety and fear for patients and their families. The European Academy of Allergy and Clinical Immunology (EAACI) and the European Respiratory Society (ERS) set up a task force to search for a clear definition of severe exacerbations, and to also define research questions and priorities. The statement includes comments from patients who were members of the task force.
Copyright ©ERS 2019.

Entities:  

Year:  2019        PMID: 31467120     DOI: 10.1183/13993003.00900-2019

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  17 in total

1.  Analysis of the Mechanism of Zhichuanling Oral Liquid in Treating Bronchial Asthma Based on Network Pharmacology.

Authors:  Ruiyin Wang; Jiangtao Lin
Journal:  Evid Based Complement Alternat Med       Date:  2020-01-17       Impact factor: 2.629

Review 2.  Precision medicine in severe pediatric asthma: opportunities and challenges.

Authors:  Susanne J H Vijverberg; Paul Brinkman; Niels W P Rutjes; Anke H Maitland-van der Zee
Journal:  Curr Opin Pulm Med       Date:  2020-01       Impact factor: 2.868

3.  Use of Fractional Exhaled Nitric Oxide to Guide the Treatment of Asthma: An Official American Thoracic Society Clinical Practice Guideline.

Authors:  Sumita B Khatri; Jonathan M Iaccarino; Amisha Barochia; Israa Soghier; Praveen Akuthota; Anna Brady; Ronina A Covar; Jason S Debley; Zuzana Diamant; Anne M Fitzpatrick; David A Kaminsky; Nicholas J Kenyon; Sandhya Khurana; Brian J Lipworth; Kevin McCarthy; Michael Peters; Loretta G Que; Kristie R Ross; Elena K Schneider-Futschik; Christine A Sorkness; Teal S Hallstrand
Journal:  Am J Respir Crit Care Med       Date:  2021-11-15       Impact factor: 21.405

4.  Real-world benefits of biologics for asthma: Exacerbation events and systemic corticosteroid use.

Authors:  Yuya Kimura; Maho Suzukawa; Norihiko Inoue; Shinobu Imai; Manabu Akazawa; Hirotoshi Matsui
Journal:  World Allergy Organ J       Date:  2021-11-05       Impact factor: 4.084

Review 5.  Review of Perioperative Music Medicine: Mechanisms of Pain and Stress Reduction Around Surgery.

Authors:  J P Ginsberg; Karthik Raghunathan; Gabriel Bassi; Luis Ulloa
Journal:  Front Med (Lausanne)       Date:  2022-02-04

6.  Biologics in Severe Eosinophilic Asthma: Three-Year Follow-Up in a SANI Single Center.

Authors:  Paolo Solidoro; Stefania Nicola; Irene Ridolfi; Giorgio Walter Canonica; Francesco Blasi; Pierluigi Paggiaro; Enrico Heffler; Diego Bagnasco; Filippo Patrucco; Fulvia Ribolla; Caterina Bucca; Giovanni Rolla; Carlo Albera; Luisa Brussino
Journal:  Biomedicines       Date:  2022-01-18

7.  Allergen immunotherapy during the COVID-19 pandemic-A survey of the German Society for Allergy and Clinical Immunology.

Authors:  Oliver Pfaar; Eckard Hamelmann; Ludger Klimek; Christian Taube; Christian Vogelberg; Martin Wagenmann; Thomas Werfel; Margitta Worm
Journal:  Clin Transl Allergy       Date:  2022-03       Impact factor: 5.871

8.  Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme.

Authors:  Camille Taillé; Pascal Chanez; Gilles Devouassoux; Alain Didier; Christophe Pison; Gilles Garcia; Jeremy Charriot; Stéphane Bouée; Alina Gruber; Celine Pribil; Arnaud Bourdin; Marc Humbert
Journal:  Eur Respir J       Date:  2020-06-25       Impact factor: 16.671

9.  Clinical and daily respiratory care and clinical trials within the COVID-19 era.

Authors:  Zuzana Diamant; Vibeke Backer; Leif Bjermer
Journal:  Eur Clin Respir J       Date:  2020-05-25

10.  COVID-19 pandemic: Practical considerations on the organization of an allergy clinic-An EAACI/ARIA Position Paper.

Authors:  Oliver Pfaar; Ludger Klimek; Marek Jutel; Cezmi A Akdis; Jean Bousquet; Heimo Breiteneder; Sharon Chinthrajah; Zuzana Diamant; Thomas Eiwegger; Wytske J Fokkens; Hans-Walter Fritsch; Kari C Nadeau; Robyn E O'Hehir; Liam O'Mahony; Winfried Rief; Vanitha Sampath; Manfred Schedlowski; María José Torres; Claudia Traidl-Hoffmann; De Yun Wang; Luo Zhang; Matteo Bonini; Randolf Brehler; Helen Annaruth Brough; Tomás Chivato; Stefano R Del Giacco; Stephanie Dramburg; Radoslaw Gawlik; Aslı Gelincik; Karin Hoffmann-Sommergruber; Valerie Hox; Edward F Knol; Antti Lauerma; Paolo M Matricardi; Charlotte G Mortz; Markus Ollert; Oscar Palomares; Carmen Riggioni; Jürgen Schwarze; Isabel Skypala; Eva Untersmayr; Jolanta Walusiak-Skorupa; Ignacio J Ansotegui; Claus Bachert; Anna Bedbrook; Sinthia Bosnic-Anticevich; Luisa Brussino; Giorgio Walter Canonica; Victoria Cardona; Pedro Carreiro-Martins; Alvaro A Cruz; Wienczyslawa Czarlewski; João A Fonseca; Maia Gotua; Tari Haahtela; Juan Carlos Ivancevich; Piotr Kuna; Violeta Kvedariene; Désirée Erlinda Larenas-Linnemann; Amir Hamzah Abdul Latiff; Mika Mäkelä; Mário Morais-Almeida; Joaquim Mullol; Robert Naclerio; Ken Ohta; Yoshitaka Okamoto; Gabrielle L Onorato; Nikolaos G Papadopoulos; Vincenzo Patella; Frederico S Regateiro; Bolesław Samoliński; Charlotte Suppli Ulrik; Sanna Toppila-Salmi; Arunas Valiulis; Maria-Teresa Ventura; Arzu Yorgancioglu; Torsten Zuberbier; Ioana Agache
Journal:  Allergy       Date:  2021-03       Impact factor: 14.710

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.